Lucid Diagnostics Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that it issued a press release announcing advances in payment, billing, and coding pathways for its EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device.

Key Highlights

  • Products covered: The announcement pertains to the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device.
  • Pathway advances: The company disclosed advances in "multiple payment, billing, and coding pathways," according to the filing.
  • Triggering events: The advances followed three public meetings held the week prior to September 22, 2026.
  • Disclosure type: The information was furnished under Regulation FD (Item 7.01) and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signatory: The filing was signed by Dennis McGrath, Chief Financial Officer of Lucid Diagnostics Inc.

Lucid Diagnostics Discloses Billing and Coding Pathway Developments for Esophageal Testing Products

Lucid Diagnostics Inc. (NASDAQ:LUCD), a Delaware-incorporated company headquartered at 360 Madison Avenue, 25th Floor, New York, New York 10017, filed a current report on September 22, 2026. According to the filing, the company issued a press release on that same date announcing advances in "multiple payment, billing, and coding pathways" for its EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device.

The filing indicates that these advances came following three public meetings held the week prior to the report date. No additional details regarding the specific content or outcomes of those meetings were included in the body of the 8-K itself; the full press release was attached as Exhibit 99.1 and incorporated by reference. The company noted that the information furnished under Item 7.01, including the attached exhibit, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Lucid Diagnostics is identified in the filing as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act, according to the filing.

What Was Disclosed

Lucid Diagnostics filed an 8-K on September 22, 2026, disclosing a press release about payment, billing, and coding pathway advances for EsoGuard and EsoCheck, following three public meetings. The disclosure was furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act.